ADCs in Development for the Treatment of Lung Cancer
Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.
EP: 1.Overview of Antibody Drug Conjugates in Lung Cancer
Now Viewing
EP: 2.ADCs in Development for the Treatment of Lung Cancer
EP: 3.Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
EP: 4.HER2-Directed Agents in NSCLC
EP: 5.Targeting HER3 in EGFR-Mutant NSCLC
EP: 6.Exploring TROP2 Expression in Patients with NSCLC
Related Videos
Related Content
